The Need for Breathing Retraining: the Elephant in the Cardiac Rehabilitation Room

Sponsor
Cairo University (Other)
Overall Status
Completed
CT.gov ID
NCT04905433
Collaborator
National Heart Institute, Egypt (Other)
40
1
2
9
4.4

Study Details

Study Description

Brief Summary

As an extension of previous work, in this study, a breathing retraining component is added using breathing calisthenics and inspiratory muscle trainer for the classical cardiac rehabilitation (CR), as an appealing option, to implement a comprehensive rehabilitation protocol addressing the different patient-centered outcomes including different cardiovascular, and respiratory complaints; increasing the benefits of classical CR; detecting the impact of adding this on the cardiovascular (CV) outcomes, and discovering the correlation between the CV and respiratory data.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cardiac rehabilitation with breathing retraining
  • Behavioral: Cardiac rehabilitation
N/A

Detailed Description

A very large number of studies have demonstrated the positive effect of cardiac rehabilitation (CR) and pulmonary rehabilitation (PR) on morbidity and mortality. Globally, each year millions of patients with different cardiovascular diseases (CVD) and chest diseases are enrolled in these programs. The exact effects may be slightly variable, but generally, both CR and PR aim to improve the patient's condition and improve the overall quality of life utilizing almost the same methods (exercise, and education).

Despite these positive effects, utilization rates of either CR or PR are around 30% in Europe, with much less percentages in the Middle East. The reasons for the low engagement rates are many; with most probably the main reasons are about individuality and reach. Optimized CR programs have to be individually tailored; meeting the individual needs of every single patient in the program. Worse knowing that the chest pain and breathlessness are highly prevalent in general in CVD, and considered -in many cases as the chief complaint, and the classical CR programs are neglecting these complaints; negatively affecting adherence rates and patient-centered outcomes (PCO) which mostly extend much beyond the cardiovascular complaints, to extend to the respiratory, and sleep complaints; questioning the reason why breathing retraining methods are not yet considered as an integral part of the CR programs.

The reason that standard CR programs usually neglect these complaints, and only look for the CV outcomes; is considering the other mentioned complaints as "out-of-context". However, solid evidence is suggesting a strong correlation between respiratory, sleep, and CV outcomes.

It has been previously investigated the impact of the CR on sleep, and there is a prior estimate suggesting that 25% of the participants in the CR programs have already sleep disorders, there is a strong correlation between the sleep and CV outcomes, and almost all of the patients in the CR have respiratory symptoms including dyspnea and functional capacity decline.

Therefore, it was suggested adding a breathing retraining component using breathing calisthenics and inspiratory muscle trainer for the classical CR, as an appealing option, to implement a comprehensive rehabilitation protocol addressing the different PCO including different cardiovascular, and respiratory complaints; increasing the benefits of classical CR; detecting the impact of adding this on the CV outcomes, and discovering the correlation between the CV and respiratory data.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Care Provider)
Primary Purpose:
Treatment
Official Title:
The Need for Breathing Retraining: the Elephant in the Cardiac Rehabilitation Room
Actual Study Start Date :
Jun 1, 2019
Actual Primary Completion Date :
Mar 1, 2020
Actual Study Completion Date :
Mar 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cardiac rehabilitation with breathing retraining

A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)

Behavioral: Cardiac rehabilitation with breathing retraining
A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)

Active Comparator: cardiac rehabilitation

A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only

Behavioral: Cardiac rehabilitation
A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only

Outcome Measures

Primary Outcome Measures

  1. heart rate variability [12 weeks]

    represent autonomic response of the heart (measured through a holter ECG)

  2. functional capacity [12 weeks]

    represents aerobic fitness (VO2 max) (ml/kg/min) measured through cardiopulmonary exercise testing

  3. anaerobic threshold [12 weeks]

    represents lactate threshold (% of VO2 max) measured through cardiopulmonary exercise testing

  4. resting heart rate [12 weeks]

    represents resting condition of the heart (beat/min)

  5. resting systolic blood pressure [12 weeks]

    represents resting condition of the systolic blood pressure (mmhg) measured by sphygmomanometer

  6. resting diastolic blood pressure [12 weeks]

    represents resting condition of the diastolic blood pressure (mmhg) measured by sphygmomanometer

Secondary Outcome Measures

  1. forced vital capacity [12 weeks]

    represents volume of air in a forced expiration after full inspiration (%) measured by pulmonary function testing

  2. rate of perceived exertion [12 weeks]

    represents level of patient exertion on exercise measured by modified Borg scale (1-10), where lower scores means lower levels of exertion, and higher scores means higher levels of exertion.

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • . chronic heart failure (≥ 1 year) .Respiratory muscle weakness≤ 70% of their predicted MIP.

  • Ages ranged from 45-65 years old

  • Left ventricle ejection fraction ≤ 40% in NYHA class II and III .In stable condition (No rales on auscultation or tibial edema and with sinus rhythm).

  • On standard cardiac medications (diuretics, angiotensin-converting enzyme (ACE) inhibitors, and glycosides)

  • Not engaged in any regular physical training program for at least one month before the start of the study.

Exclusion Criteria:
  • Chronic lung disorders,

  • Anemia

  • Severe hypoxia

  • History of myocardial infarction or pulmonary edema six months before the study

  • Severe uncontrolled hypertension, or uncontrolled diabetes mellitus or autonomic disorders

Contacts and Locations

Locations

Site City State Country Postal Code
1 National heart institute Cairo AI Qahirah Egypt 11847

Sponsors and Collaborators

  • Cairo University
  • National Heart Institute, Egypt

Investigators

  • Principal Investigator: Hady Atef, PhD, Cairo University, Egypt
  • Study Director: Donna Fitzimons, Prof, Queen's University Belfast, UK

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hady Atef Labib, Lecturer of physical therapy for cardiopulmonary disorders, Faculty of Physical therapy, Cairo University
ClinicalTrials.gov Identifier:
NCT04905433
Other Study ID Numbers:
  • IMT and CR
First Posted:
May 27, 2021
Last Update Posted:
Jan 25, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hady Atef Labib, Lecturer of physical therapy for cardiopulmonary disorders, Faculty of Physical therapy, Cairo University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 25, 2022